$CNXX
CONX Corp.

2021 Q2 Form 10-Q Financial Statement

#000110465921104354 Filed on August 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $230.2K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $230.2K
YoY Change
Operating Profit -$230.2K
YoY Change
Interest Expense -$3.591M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$3.591M
YoY Change
Pretax Income -$3.821M
YoY Change
Income Tax $4.905K
% Of Pretax Income
Net Earnings -$3.826M
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$40.81K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $894.6K
YoY Change
Cash & Equivalents $894.6K
Short-Term Investments
Other Short-Term Assets $49.33K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $947.5K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $750.0M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $750.0M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $947.5K
Total Long-Term Assets $750.0M
Total Assets $751.0M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00
YoY Change
Accrued Expenses $150.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $154.7K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $67.14M
YoY Change
Total Long-Term Liabilities $67.14M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $154.7K
Total Long-Term Liabilities $67.14M
Total Liabilities $67.29M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $4.997M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$66.30M
YoY Change
Total Liabilities & Shareholders Equity $751.0M
YoY Change

Cashflow Statement

Concept 2021 Q2
OPERATING ACTIVITIES
Net Income -$3.826M
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$137.2K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -137.2K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -137.2K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$137.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001823000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
conxu Threshold Trading Days For Redeem Public Shares After Completion Of Initial Business Combination
ThresholdTradingDaysForRedeemPublicSharesAfterCompletionOfInitialBusinessCombination
P10D
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39677
dei Entity Registrant Name
EntityRegistrantName
CONX CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-2728630
dei Entity Address Address Line1
EntityAddressAddressLine1
5701 S
dei Entity Address Address Line2
EntityAddressAddressLine2
Santa Fe Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Littleton
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80120
dei City Area Code
CityAreaCode
303
dei Local Phone Number
LocalPhoneNumber
472-1542
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
894640
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1211837
CY2021Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
49333
CY2020Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
22333
CY2021Q2 us-gaap Other Receivables
OtherReceivables
3508
CY2020Q4 us-gaap Other Receivables
OtherReceivables
3508
CY2021Q2 us-gaap Assets Current
AssetsCurrent
947481
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1237678
CY2021Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
750042745
CY2020Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
750005343
CY2021Q2 us-gaap Assets
Assets
750990226
CY2020Q4 us-gaap Assets
Assets
751243021
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
112500
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
150000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25000
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4662
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1122
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
154662
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
138622
CY2021Q2 conxu Deferred Legal Fees
DeferredLegalFees
275000
CY2020Q4 conxu Deferred Legal Fees
DeferredLegalFees
275000
CY2021Q2 conxu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
26250000
CY2020Q4 conxu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
26250000
CY2021Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
40612499
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
45726666
CY2021Q2 us-gaap Liabilities
Liabilities
67292161
CY2020Q4 us-gaap Liabilities
Liabilities
72390288
CY2021Q2 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.00
CY2020Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.00
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8671529
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
5000004
CY2021Q2 conxu Shares Subject To Redemption Value
SharesSubjectToRedemptionValue
-3826199
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3826198
us-gaap Net Income Loss
NetIncomeLoss
4845332
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5000003
CY2021Q1 conxu Shares Subject To Redemption Value
SharesSubjectToRedemptionValue
8671528
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2879871
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4997415
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2117495
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
5000005
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5000003
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
750990226
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
751243021
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
230200
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
296772
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-230200
us-gaap Operating Income Loss
OperatingIncomeLoss
-296772
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3610000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5114167
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
18907
us-gaap Investment Income Interest
InvestmentIncomeInterest
37402
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3591093
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5151569
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3821293
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4854797
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4905
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9465
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3826198
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
5000005
us-gaap Profit Loss
ProfitLoss
4845332
us-gaap Investment Income Interest
InvestmentIncomeInterest
37402
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5114167
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
27000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-112500
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
125000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3540
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-317197
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-317197
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1211837
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
894640
conxu Change In Value Of Common Stock Subject To Possible Redemption
ChangeInValueOfCommonStockSubjectToPossibleRedemption
4845330
CY2020Q4 conxu Investment Maturity Period Of Initial Public Offering Proceeds Minimum
InvestmentMaturityPeriodOfInitialPublicOfferingProceedsMinimum
P185D
conxu Investment Maturity Period Of Initial Public Offering Proceeds Minimum
InvestmentMaturityPeriodOfInitialPublicOfferingProceedsMinimum
P185D
CY2021Q2 conxu Business Combination Percent To Trust Account
BusinessCombinationPercentToTrustAccount
0.80
conxu Percent Of Difference Between Total Return And Price Threshold Multiplied By Sum Of Any Stock Splits Stock Capitalizations Stock Combinations Stock Dividends Reorganizations Recapitalizations
PercentOfDifferenceBetweenTotalReturnAndPriceThresholdMultipliedBySumOfAnyStockSplitsStockCapitalizationsStockCombinationsStockDividendsReorganizationsRecapitalizations
0.20
CY2021Q2 conxu Business Combination Post Transaction Company Minimum Ownership
BusinessCombinationPostTransactionCompanyMinimumOwnership
0.50
CY2021Q2 conxu Redemption Price Of Shares Sold In Initial Public Offering
RedemptionPriceOfSharesSoldInInitialPublicOffering
10.00
conxu Minimum Net Tangible Assets Upon Consummation Of Business Combination
MinimumNetTangibleAssetsUponConsummationOfBusinessCombination
5000001
conxu Obligation To Redeem Percentage Of Common Stock With Respect To Any Other Material Provision Relating To Stockholders Rights Or Pre Initial Business Combination Activity
ObligationToRedeemPercentageOfCommonStockWithRespectToAnyOtherMaterialProvisionRelatingToStockholdersRightsOrPreInitialBusinessCombinationActivity
1
CY2021Q2 conxu Redemption Price Of Shares Sold In Initial Public Offering
RedemptionPriceOfSharesSoldInInitialPublicOffering
10.00
CY2021Q2 conxu Redemption Price Of Shares Sold In Initial Public Offering
RedemptionPriceOfSharesSoldInInitialPublicOffering
10.00
conxu Minimum Net Tangible Assets Upon Consummation Of Business Combination
MinimumNetTangibleAssetsUponConsummationOfBusinessCombination
5000001
conxu Redemption Of Percentage Of Common Stock Included In Units Sold In Offering
RedemptionOfPercentageOfCommonStockIncludedInUnitsSoldInOffering
0.15
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. At June 30, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2021Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
250000
us-gaap Derivatives Methods Of Accounting Hedging Derivatives
DerivativesMethodsOfAccountingHedgingDerivatives
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value as of the IPO (November 3, 2020) and re-valued at each reporting date, with changes in the fair value reported in the condensed Statements of Operations. Derivative assets and liabilities are classified on the Balance Sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the Balance Sheet date. The Company has determined the Warrants are a derivative instrument. As the Warrants meet the definition of a derivative the Warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the Statement of Operations in the period of change.</p>
conxu Investment Maturity Period Of Initial Public Offering Proceeds Minimum
InvestmentMaturityPeriodOfInitialPublicOfferingProceedsMinimum
P185D
CY2021Q2 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
1.00
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities during the reporting period. The determination of the fair value of the warrant liabilities is a significant accounting estimate included in these financial statements. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p>
conxu Founder Shares Hold Period From Business Combination
FounderSharesHoldPeriodFromBusinessCombination
P180D
CY2021Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 conxu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
26300000
conxu Threshold Period For Not To Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination
ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination
P30D
CY2021Q2 conxu Cash Underwriting Discount Per Unit
CashUnderwritingDiscountPerUnit
0.20
conxu Payment Of Underwriter Discount
PaymentOfUnderwriterDiscount
15000000
CY2021Q2 conxu Deferred Fee Per Unit
DeferredFeePerUnit
0.35
CY2021Q2 conxu Deferred Legal Fees
DeferredLegalFees
275000
CY2020Q4 conxu Deferred Legal Fees
DeferredLegalFees
275000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
40612499
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
45726666
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0

Files In Submission

Name View Source Status
0001104659-21-104354-index-headers.html Edgar Link pending
0001104659-21-104354-index.html Edgar Link pending
0001104659-21-104354.txt Edgar Link pending
0001104659-21-104354-xbrl.zip Edgar Link pending
conxu-20210630.xsd Edgar Link pending
conxu-20210630x10q.htm Edgar Link pending
conxu-20210630x10q_htm.xml Edgar Link completed
conxu-20210630xex31d1.htm Edgar Link pending
conxu-20210630xex32d1.htm Edgar Link pending
conxu-20210630_cal.xml Edgar Link unprocessable
conxu-20210630_def.xml Edgar Link unprocessable
conxu-20210630_lab.xml Edgar Link unprocessable
conxu-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending